Expert Insights

Andrea Casadei-Gardini, MD, San Raffaele Research Hospital

Videos

Real-World Efficacy and Safety of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer

09/22/2023

Featuring Andrea Casadei-Gardini, MD

Featuring Andrea Casadei-Gardini, MD ...

A real-world analysis of durvalumab plus gemcitabine-cisplatin confirmed the results seen in previous clinical trials, supporting the use of this combination in clinical practice.

A real-world analysis of...

09/22/2023

Oncology

Videos

Exploring the Role of FGFR1 as a Therapeutic Target Among Patients With MCL

09/22/2023

Featuring Narendranath Epperla, MD, MS

Featuring Narendranath Epperla, MD, M...

Narendranath Epperla, MD, MS, discusses the current research on fibroblast growth factor receptor-1 as an up-and-coming and viable therapeutic target for patients with mantle cell lymphoma.

Narendranath Epperla, MD, MS,...

09/22/2023

Oncology

Videos

Updates on the Safety, Efficacy of Mosunetuzumab Therapy for Patients With R/R Follicular Lymphoma

09/22/2023

Featuring Matthew Matasar, MD

Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma.

Matthew Matasar, MD, shares...

09/22/2023

Oncology

Videos

Novel Developments in the Multiple Myeloma Treatment Landscape

09/15/2023

Featuring Andrew Yee, MD

Andrew Yee, MD, discusses new developments and possibilities in the treatment landscape for patients with multiple myeloma at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.

Andrew Yee, MD, discusses new...

09/15/2023

Oncology

Eugene Koay, MD, PhD, MD Anderson Cancer Center

Videos

Definitive Radiotherapy for Intrahepatic Cholangiocarcinoma With Extrahepatic Metastases

09/14/2023

Featuring Eugene Koay, MD, PhD

Featuring Eugene Koay, MD, PhD ...

Eugene Koay, MD, PhD, discusses a study which found liver radiotherapy for patients with intrahepatic cholangiocarcinoma and extrahepatic metastases was associated with a longer overall survival, compared with chemotherapy alone.

Eugene Koay, MD, PhD, discusses...

09/14/2023

Oncology

Videos

Antitumor Activity of Amivantamab Among Patients With METex14 Non-Small Cell Lung Cancer

09/13/2023

Featuring Alexander Spira, MD, PhD

Featuring Alexander Spira, MD, PhD ...

Alexander Spira, MD, PhD, discusses the efficacy of amivantamab among patients with METex14 NSCLC enrolled in the CHRYSALIS study, as presented at the 2023 World Conference on Lung Cancer.

Alexander Spira, MD, PhD,...

09/13/2023

Oncology

Videos

Promising Advances in the Treatment of Patients With Mantle Cell Lymphoma

09/13/2023

Featuring Michael Wang, MD

At the 2023 Society of Hematologic Oncology Annual Meeting, Michael Wang, MD, reviews the latest research and treatment advances for patients with mantle cell lymphoma.

At the 2023 Society of...

09/13/2023

Oncology

Videos

Amivantamab, Lazertinib, and Chemotherapy Quadruplet Therapy Demonstrated Durable Response Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer

09/13/2023

Featuring Alexander Spira, MD, PhD

Featuring Alexander Spira, MD, PhD ...

Alexander Spira, MD, PhD, discusses updated results from the CHRYSALIS-2 study, in which amivantamab and lazertinib plus chemotherapy demonstrated durable and meaningful responses among patients with EGFR-mutated NSCLC, as presented at the...

Alexander Spira, MD, PhD,...

09/13/2023

Oncology

Videos

Addition of Perioperative Durvalumab to Neoadjuvant Chemotherapy Did Not Adversely Affect Surgical Outcomes Among Patients With Resectable Non-Small Cell Lung Cancer

09/12/2023

Featuring Tetsuya Mitsudomi, MD, PhD

Featuring Tetsuya Mitsudomi, MD, PhD ...

At the 2023 World Conference on Lung Cancer, Tetsuya Mitsudomi, MD, PhD, presented results which demonstrated the addition of perioperative durvalumab to neoadjuvant chemotherapy did not adversely affect surgical outcomes among patients with...

At the 2023 World Conference on...

09/12/2023

Oncology

Videos

Exploring Potential Novel Therapeutic Interventions for Patients With Early-Stage Myelodysplastic Syndromes

09/12/2023

Featuring Juan Jose Rodriguez-Sevilla, PhD

Featuring Juan Jose Rodriguez-Sevilla...

Therapies targeting the biological mechanisms of pre-leukemic MDS may improve patient outcomes, according to data presented at the SOHO 2023 annual meeting by Juan Jose Rodriguez-Sevilla, PhD.

Therapies targeting the...

09/12/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology